JPT Peptide Technologies

For over 20 years, JPT Peptide Technologies has led peptide synthesis innovation, offering patented technologies for peptide libraries, pools, and microarrays. We support cancer immunotherapy, vaccine development, immunomonitoring, and cell therapy development with comprehensive peptide libraries and clinical-grade peptides.

Our PepMixes, available for Adenoviruses, AAVs, and other vectors, are ideal tool for immunogenicity studies and vector-based therapy development.

Our clinical-grade peptides are the preferred choice for cell therapies such as adoptive cell transfer or dendritic cell pulsing, whether targeting individualized neo-epitopes or shared antigens.

Travertide™, our novel transduction enhancer and newest member of the product family, streamlines CAR-T and TCR-T generation with a simple one-step viral transduction protocol and cell-pentrating peptides support delivery of your cargo.

Based in Berlin, Germany, our ISO 9001:2015 laboratories offer micro- to intermediate-scale peptide synthesis (10 nmol – 100 mg) with high throughput up to 1 million peptides annually, customizable formats, purities, and modifications.